MedTrace Logo

A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery

NCT00260988 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2014-09-10

No results posted yet for this study

Summary

The purpose of this study is to better understand if either dalteparin or tinzaparin is a better drug to use in dialysis patients on blood thinners who are at high risk of developing blood clots and need surgery.

Conditions

  • Thromboembolism
  • Hemodialysis

Interventions

DRUG

Fragmin (dalteparin)

200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery

DRUG

Innohep (tinzaparin)

175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Marc Rodger, MD, MSc · OHRI

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00260988 on ClinicalTrials.gov